Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AdvisorShares Psychedelics ETF (NY:PSIL)

13.96 -0.27 (-1.86%)
Streaming Delayed Price Updated: 11:59 AM EDT, Jun 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AdvisorShares Psychedelics ETF

< Previous 1 2 3 4 5 Next >
Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts
The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it. 
Via Stocktwits
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
5 ETFs That Beat Market Turmoil With Gains Last Week
Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs. 
Via Benzinga
Topics ETFs Economy
High-Momentum ETFs Leading the Market This Year
Momentum investors looking to start 2025 off on good footing might look no further than these high-flying ETFs, each of which has returned 14% or more in 2025. 
Via MarketBeat
Topics ETFs
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding
Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 
Via Stocktwits
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish
The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms. 
Via Stocktwits
5 Best-Performing Sector ETFs Of Q4
In this article, we have highlighted five top-performing ETFs from different sectors that were the leaders in the fourth quarter. 
Via Talk Markets
Topics ETFs
Why Is Penny Stock Clearmind Gaining Today?
Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder. 
Via Benzinga
5 Best-Performing Sector ETFs Midway In Q4
In this article, we have highlighted five top-performing ETFs from different sectors that were the leaders over the past month. 
Via Talk Markets
Topics ETFs
Top And Flop ETFs Of The First Half
In this article, we have highlighted three ETFs each from the best and worst-performing zones in the first half of 2024. 
Via Talk Markets
Topics ETFs
Best And Worst ETF Zones Of Q2
After the worst monthly decline in many months in April, global stock markets have staged a nice comeback on renewed Fed rate cut bets, ongoing artificial intelligence (AI) developments and strong... 
Via Talk Markets
Topics Artificial Intelligence ETFs Economy
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. 
Via Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
Mental Health Mavericks: 3 Stocks Changing the Game
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money. 
Via InvestorPlace
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
Via Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury 
Via Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
Via Benzinga
Psychedelic Drug Stocks Index Up In December; Down YTD
The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021. 
Via Talk Markets
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
Biden To Decide On Psychedelic Therapy Bill 
Via Benzinga
Psychedelic Drug Stocks Index Declined 1.6% This Week
Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD. 
Via Talk Markets
Topics ETFs
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy 
Via Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week
The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week. 
Via Talk Markets
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Defense Dept. Funds Ketamine Study For PTSD Treatment  
Via Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan 
Via Benzinga
Topics Cannabis
GH Research Drags Down Psychedelic Drug Stocks Index By 7%
The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week. 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.